SINGLE TABLET REGIMEN COMPARISON CHART
The digital pill tray is for healthcare professionals only. It is not intended for use with patients.
The pill visuals in this app have been set in relation to the size of a 10p or 50€ cent coin depending on your selected region. The visuals may scale up or down depending on the type of device being used to view the tool, but the relative sizes will remain consistent.
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
Adverse events should be reported.
For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Gilead to safety_FC@gilead.com or +353 (0) 21 482 5999.
Product listed are full list of licensed STRs in the UK and IE as of March 2025.
UK-BVY-1155 March 2025
BIKTARVY® is indicated for the treatment of
human immunodeficiency virus 1 (HIV-1) infection
in adults and paediatric patients at least 2
years of age and weighing at least 14 kg without
present or past evidence of viral resistance to
bictegravir or tenofovir. For paediatric patients
≥ 2 years of age, weighing at least 14 kg
to less than 25 kg, the dose is one 30mg/120mg/15mg
tablet once daily.
The pill shown in this pill tray is the
50mg/200mg/25mg formulation only and not the
30mg/120mg/15mg formulation.
BIKTARVY® is indicated for the treatment of
human immunodeficiency virus 1 (HIV-1) infection
in adults and paediatric patients at least 2
years of age and weighing at least 14 kg without
present or past evidence of viral resistance to
the integrase inhibitor class, emtricitabine or
tenofovir. For paediatric patients ≥ 2
years of age, weighing at least 14 kg to less
than 25 kg, the dose is one 30mg/120mg/15mg
tablet once daily.
The pill shown in this pill tray is the
50mg/200mg/25mg formulation only and not the
30mg/120mg/15mg formulation.
EVIPLERA® is indicated for the treatment of
adults infected with human immunodeficiency
virus type 1 (HIV-1) without known mutations
associated with resistance to the non-nucleoside
reverse transcriptase inhibitor (NNRTI) class,
tenofovir or emtricitabine, and with a viral
load ≤ 100,000 HIV-1 RNA copies/mL.
Genotypic resistance testing and/or historical
resistance data should guide the use of
EVIPLERA®
GENVOYA® is indicated for the treatment of
human immunodeficiency virus-1 (HIV-1) infection
without any known mutations associated with
resistance to the integrase inhibitor class,
emtricitabine or tenofovir in adults and
paediatric patients aged from 2 years and with
body weight at least 14 kg. For paediatric
patients ≥ 2 years of age, weighing at
least 14 kg but less than 25 kg, the dose is
90mg/90mg/120mg/6mg tablet once daily.
Only
the 150mg/150mg/200mg/10mg tablet is
commercially available.
The pill shown in the pill tray is the
150mg/150mg/200mg/10mg formulation only and
not the 90mg/90mg/120mg/6mg
formulation.
ODEFSEY® is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤100,000 HIV-1 RNA copies/mL.
STRIBILD® is indicated for the treatment of
human immunodeficiency virus-1 (HIV-1) infection
in adults aged 18 years and over who are
antiretroviral treatment-naïve or are infected
with HIV-1 without known mutations associated
with resistance to any of the three
antiretroviral agents in STRIBILD®
STRIBILD® is also indicated for
the treatment of HIV-1 infection in adolescents
aged 12 to < 18 years weighing ≥ 35 kg who
are infected with HIV-1 without known mutations
associated with resistance to any of the three
antiretroviral agents in STRIBILD® and who
have experienced toxicities which preclude the
use of other regimens that do not contain
tenofovir disoproxil.
Reporting forms and information can be found at or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500
Full indications for some products may vary between the UK and IE. Please refer to product specific prescribing information via the links above for full details.
For Ireland, reporting forms and information can be found at and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Gilead to safety_FC@gilead.com +353 (0) 21 482 5999.
Full indications for some products may vary between the UK and IE. Please refer to product specific prescribing information via the links above for full details.
The digital pill tray is for healthcare professionals only. It is not intended for use with patients.
The EU SmPCs for IE can be found at the following address: .
emtricitabine (200mg)
tenofovir alafenamide (25mg)
dolutegravir (50mg)
lamivudine (300mg)
lamivudine (300mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir alafenamide (10mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
rilpivirine (25mg)
lamivudine (300mg)
tenofovir disoproxil (245mg)
emtricitabine (200mg)
tenofovir alafenamide (25mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir alafenamide (10mg)
emtricitabine (200mg)
tenofovir alafenamide (25mg)
dolutegravir (50mg)
lamivudine (300mg)
lamivudine (300mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir alafenamide (10mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
rilpivirine (25mg)
lamivudine (300mg)
tenofovir disoproxil (245mg)
emtricitabine (200mg)
tenofovir alafenamide (25mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
emtricitabine (200mg)
tenofovir disoproxil (245mg)
cobicistat (150mg)
emtricitabine (200mg)
tenofovir alafenamide (10mg)
Prescribing information for Gilead products can be found by clicking on the buttons at the top of the page.
Please report all adverse events, following or coincident with the use of any Gilead product, to Gilead Pharmacovigilance and Epidemiology at Safety_FC@gilead.com.
Go Back
How to use this tool
|
Tapping the 'i' will show further information re: the make-up of that tablet, flipping the square to reveal the components and their milligrams (mgs).
Tapping the circular radio button above the
tablet will select that tablet for
comparison. |
|
The two buttons to the left of the coin
allow for all pills to be rotated to the
side (rectangle icon) or returned to front
facing (circle icon). This allows for
further size comparison of the tablets. |
Close
Close
External Link Disclaimer.
You will now be directed to an external website
which provides additional information that is consistent
with the intended purpose of this comparison chart;
however, the external website is subject to change
beyond Gilead’s control.
Go Back